On October 30, 2018 Genomic Health, Inc. (NASDAQ: GHDX) reported that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results (Press release, Genomic Health, OCT 30, 2018, https://www.prnewswire.com/news-releases/genomic-health-to-announce-third-quarter-2018-financial-results-and-host-conference-call-on-tuesday-november-6-2018-300738438.html [SID1234530352]). The call and webcast will follow the release of the third quarter financial results after market close.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details
To access the live conference call on November 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada, or +1 (224) 357-2389 internationally. The conference call ID is 9448559. Please dial in approximately ten minutes prior to the start of the call.

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s web site at View Source Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

On October 30, 2018 Shanghai Fosun High Technology (Group) Co., Ltd. ("Fosun High Technology"), a subsidiary of Fosun International Limited (the "Company"), which has issued medium-term notes in February 2018, April 2018, July 2018 and September 2018 respectively, and super commercial paper in June 2018 in the China’s interbank bond market, published its 2018 third quarter report (the "Report") on 30 October 2018, in accordance with the relevant regulations in China (Press release, Fosun Pharma, OCT 30, 2018, View Source [SID1234530388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The board of directors of the Company (the "Board") would like to draw the attention of its shareholders and the investment public to the following unaudited principal consolidated financial data of Fosun High Technology for the nine months ended 30 September 2018 as set out below in the Report:

Unit: Thousand Yuan Currency: RMB
As at the end of
this reporting period As at the end of last year
Increase/decrease as at
the end of this reporting
period as compared
with the end of last year
(%)
Total assets 288,748,478 236,798,051 21.94%
Equity attributable to
owners of the parent 53,614,661 50,089,794 7.04%
From the beginning of
2018 up to the end of
this reporting period
From the beginning of
last year up to the end of
the same reporting period
of last year
Increase/decrease as
compared with the
same period of last year
(%)
Revenue from operation 34,250,739 23,433,701 46.16%
Profit attributable to
owners of the parent 3,863,135 3,601,006 7.28%

On October 30, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that the Company will present data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary session at the 30th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Molecular Targets and Cancer Therapeutics Symposium taking place November 13-16 in Dublin (Press release, Syros Pharmaceuticals, OCT 30, 2018, View Source [SID1234530428]). The presentation will include data on safety, pharmacokinetics and proof-of-mechanism. These data will be the first clinical data presented on a selective CDK7 inhibitor, marking a significant milestone in the development of selective CDK7 inhibitors for the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In additional poster presentations, Syros will present new preclinical data on the mechanistic rationale for SY-1365 in combination with carboplatin in ovarian cancer; the first preclinical data on its oral CDK7 inhibitor program; and the discovery of drug targets and patient subsets from its analysis of the super-enhancer landscape in ovarian cancer.

The abstract for the oral presentation on SY-1365 will remain under embargo until the day of the presentation. The abstracts for the poster presentations are now available online on the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) conference website at View Source

Details on the oral presentation are as follows:

Presentation Title: Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer
Session Date & Time: Thursday, November 15, 14:30-15:45 GMT (9:30-10:45 a.m. ET)
Presentation Time: 15:30-15:45 GMT (10:30-10:45 a.m. ET)
Session Title: Plenary Session 6: Proffered Papers
Presenter: Dejan Juric, M.D., Massachusetts General Hospital
Abstract Number: 11
Location: Auditorium, The Convention Centre Dublin

Details on the poster presentations are as follows:

Presentation Title: SY-1365, a selective CDK7 inhibitor, enhances carboplatin activity in ovarian cancer cell lines and xenografts, and transcriptionally inhibits homologous recombination repair (HRR) genes
Date & Time: Tuesday, November 13, 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET)
Session Title: Poster Session: DNA Repair Modulation
Presenter: Liv Johannessen, Ph.D., Syros
Abstract Number: 50
Location: PB-001, Exhibition Hall, The Convention Centre Dublin

Presentation Title: An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models
Date & Time: Tuesday, November 13, from 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET)
Session Title: Poster Session: Molecular Targeted Agents – PART 1
Presenter: Claudio Chuaqui, Ph.D., Syros
Abstract Number: 96
Location: PB-047, Exhibition Hall, The Convention Centre Dublin

Presentation Title: Super-enhancer landscapes of ovarian cancer reveal novel epigenomic subtypes and targets
Date & Time: Friday, November 16, from 10:00-14:00 GMT (5:00-9:00 a.m. ET)
Session Title: Poster Session: Molecular Targeted Agents – PART II
Presenter: Matthew Eaton, Ph.D., Syros
Abstract Number: 400
Location: PB-063, Exhibition Hall, The Convention Centre Dublin

On October 30, 2018 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that it will report its third quarter 2018 financial results after market close on Tuesday, November 6, 2018 (Press release, Rigel, OCT 30, 2018, View Source [SID1234530447]). Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and give a company update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants can access the live conference call by dialing (855) 892-1489 (domestic) or (720) 634-2939 (international) and using the Conference ID number 1398326. The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

On October 30, 2018 NewLink Genetics Corporation (NASDAQ:NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, reported it will present at the Stifel 2018 Healthcare Conference (Press release, NewLink Genetics, OCT 30, 2018, View Source [SID1234530682]). The conference is being held on November 13 – 14 at the Lotte New York Palace Hotel in New York City, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NewLink’s management will participate in an analyst-led fireside chat Tuesday, November 13, 2018 from 11:45 AM – 12:25 PM ET and will be available for one-on-one meetings with investors who are registered to attend the conference.

A live webcast of the conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the "Investors & Media" section under "Events & Presentations".